Health News
A Change in REMS Requirements
The US Food and Drug Administration (FDA) has lifted the Risk Evaluation and Mitigation Strategy (REMS) requirements for certain medications used to treat anemia.
Merck Reports Phase III Results With Vicrelis
Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS ( boceprevir ) in combination with PEGINTRON ( peginterferon alfa-2b ) and ribavirin (P/R).